Vanessa Nicolin1*
Nunziatina De Tommasi2
Stefania Lucia Nori2
Fulvia Costantinides3
Federico Berton3Roberto Di Lenarda1- 1Clinical Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy
- 2Pharmacy-DIFARMA Department, University of Salerno, Fisciano, Italy
- 3School of Dental Sciences, University of Trieste, Trieste, Italy
During the past, a more comprehensive knowledge of mechanisms implicated in bone resorption processes has driven researchers to develop a compound library of many small molecules that specifically interfere with the genesis of osteoclast precursors cells. Natural compounds that suppress osteoclast commitment may have therapeutic value in treating pathologies associated with bone resorption like osteoporosis, rheumatoid arthritis, bone metastasis, and periodontal disease. The present review is focused on the current knowledge on the polyphenols derived from plants that could be efficacious in suppressing osteoclast differentiation and bone resorption.
Introduction
Bone Cells and Cell Guest Outsider
The strength and integrity of the human skeleton depends on a delicate balance between bone resorption and formation. Bone resorption represents a final step due to the interaction between cells that involve resorption of bone (osteoclasts, OC), and that synthetize bone matrix (osteoblasts, OB). Bone remodeling allows to adapt bone tissue to mechanical forces and to maintain phosphocalcic homeostasis through coordinated steps of formation and resorption (1, 2).
This equilibrium is close controlled by physical parameters (i.e., mechanical stimulations) and several polypeptides (hormones, cytokines) (3, 4). In addition, bone remodeling cycle maintains the integrity of the skeleton through the balanced action of its cell types.
Cells responsible for bone resorption include (1) bone-forming osteoblast, a cell that produces the organic bone extracellular matrix; (2) the bone resorbing osteoclast that dissolves bone mineral and enzymatically degrades extracellular matrix and inorganic components (5); (3) osteocyte, the maturative phase of osteoblast that acts as a mechanosensor and like an endocrine cell (6); (4) the bone lining cell, that probably may have a role in coupling bone resorption to bone formation (7).
Basically, osteoblasts and osteoclasts (and their precursors) are the central players of bone remodeling and each factor that affects these cells, in the end, affects all the process.
Numerous signaling pathways carry on the activities of osteoblast and osteoclast cells and these include nuclear factor kappa-light-chain-enhancer of activated B cells (RANkL) and Bone Morphogenetic Protein (BMP) (8). RANkL/RANK signaling axes regulates osteoclast recruitment and sustenance in normal bone modeling and remodeling and is adversely regulated by osteoprotegerin (OPG) (9).
An asymmetry between bone resorption and formation can result in bone diseases for instance in osteoporosis and in other bone resorbing pathologies.
Osteoporosis appears to be related with an impairment of bone mass through the reduction of osteogenesis and an enhancement of osteoclastic bone resorption, which results in bone fractures (10). At the present treatment options are limited, having issues with their efficacy, and long-term use. For example, the antiresorptive drugs are efficacious in reducing fracture risk (11, 12). Anti-resorptive agents, such as bisphosphonates and denosumab decrease bone loss through the inhibition of the differentiation and catabolic activity of osteoclasts in part by promoting osteoclast apoptosis. Since bone formation is coupled to bone resorption, inhibition of bone resorption is followed by a decrease in osteoblast activity that affects to adequately restore bone mass and bone quality due to increased microdamage collagen formation (13).
By considering papers on adverse effects of pharmacotherapy (estrogens, bisphosphonates) in the treatment of osteoporosis, there is an increasing request for complementary and alternative medicine.
Plant based therapies (i.e., Polyphenols) are safe options at the common treatment of osteoporosis thanks to diminished side effects and costs; in this context various plant components have been assessed for their potential role in the management of osteoporosis. Polyphenols are phytochemicals normally found in the plant kingdom, whose several biological effects have been reported to be protective against chronic diseases, including neurodegenerative and cardiovascular pathologies, cancer, and bone resorption pathologies (14). Depending on the number of phenol rings they comprehend and on the radicals bound to them, polyphenols can be split into different groups: phenolic acids, flavonoids, stilbenes, tannins, coumarins, and lignans. Recent papers based on molecular characteristics of dietary polyphenols have outlined the advantage in their prevention and management of bone resorption diseases (15). Polyphenols can safeguard bone integrity through the decreasing of oxidative stress, the reduction of inflammation by proinflammatory signaling and the modulation of osteoblastogenesis/osteoclastogenesis, by an osteoimmunological action.
The aim of this review paper was achieved on the development of osteoclast-targeting plant polyphenols that could be a great value for the prevention or treatment of bone resorption.
Methods
Studies for this narrative review were screened using the online database PubMed. Keywords used to search for articles included bone, polyphenols, iicarin, green tea polyphenols, anthocyanins, phloridzin, oleuropein, resveratrol, quercitrin, plorydzin, dried plum, citrus flavonoid, osteoblasts, osteoclasts, bone remodeling, bone resorption, periodontal disease, osteoporosis, oral health. Articles were selected based on the two aspects of the review (cellular and molecular behavior—clinical relevant scenarios). To discuss the cellular characteristics of the bone, milieu articles were selected based on how well they delineate the subject matter. Experimental studies dealing with the impact of polyphenols activity on bone cellular signaling were included. For the remaining section, were included studies based on the broadest spectrum of clinical applications presented and on the strength of evidence provided. Since the topic is relative newborn in its clinical utilization, most of the selected studies were in vitro.
Polyphenol Compounds and Bone Metabolism
Polyphenols are natural molecules derived from plants isolated and characterized in the fruits, and vegetables. Bioactive phenolic compounds were known as health benefit components due to their antioxidant and anti-inflammatory features. Up to now, there are almost 8,000 recognized polyphenols of which ~500 are biologically active. They can be obtained from plentiful natural sources and even from food/ beverage industrial products with low costs, thus using resources in a feasible way (16). They can preserve bone health by the action of five possible mechanisms: (i) by decreasing of bone loss through the activity of antioxidants, (ii) by diminishing bone loss through anti-inflammatory action, (iii) by improving osteoblastogenesis, (iv) by reducing osteoclastogenesis, and (v) through osteoimmunological activity. Many flavonoids substances have displayed positive impact on bone metabolism. For example, dietary soy isoflavones suppress bone depletion in rodents and post-menopausic women (17). One of the most studied bioactive compounds during recent years is iicarin, a heavy flavonoid component of Chinese tea, which has been reported to have intriguing osteogenic properties both in vitro and in vivo (18–21).
Recent researches have identified molecular targets in cell signaling pathways that influence bone structure. Some bioactive compounds seem to have bone anabolic action, which has important implications beyond the inhibition of bone resorption through suppressing osteoclast activation. Probably, the positive actions of these compounds are mainly due to their antioxidant characteristics, since they can act as scavengers of reactive oxygen species (ROS). Considering these properties polyphenols could affect bone metabolism through impairment of inflammatory mediators (22), such as cytokines, primarily involved in supporting osteoclast differentiation and resorption (23), consequently enabling to a decrease in bone resorption (Figure 1). Curcumin, for example, can enhance several aspects of bone health in subjects with osteoporosis by acting on different steps in the recruitment and activation of osteoclast cells, increasing mineral density and mechanical strength. Mechanisms that have been suggested involve the downregulation of NF-κB, RANKL, NO production of reactive oxygen species and inflammatory cytokine synthesis (24, 25).
Figure 1. Schematic pathway illustrating the action of polyphenols on bone remodeling.
Moreover, a lot of research has recently focused on the use of plum extract due to its high polyphenol content. Graef et al. (26) demonstrated that the polyphenolic extract from dried plums is responsible for reducing osteoclast differentiation and activity through a process of downregulation of osteoclast differentiation acting on the primary bone marrow–cells. In according with other studies, this which was mediated through the suppression of Nfatc1, that is the regulator of osteoclast differentiation process (27).
Clinical Aspects
Osteoporosis
Strategies to avoid osteoporosis include decreasing bone loss induced by acute post-menopause estrogen deficiency. As for other chronic diseases, there is increasing indication that inflammation could be part of the etiology of osteoporosis (28). In particular, oxidative stress regulates the promotion of an enhancement in bone resorption, differentiation, and activity of osteoclast cells, so it has a substantial influence on the incidence of osteoporosis. In general, oxidative stress is described as the state of asymmetry between pro-oxidants and antioxidants. It is assumed that there is a correlation between reactive oxygen species (ROS) and its pathogenesis (29). Polyphenols are able of scavenging ROS and downregulating inflammatory cytokine, including osteoclast differentiation factors, including OPG, TNF-α, RANKL (30). For these reasons, antioxidant-rich foods may represent a possible approach for slowing down age-related bone mass reduction and enhancing bone remodeling. Dietary polyphenols have been related with bone health, which may be in part imputable to their antioxidant capability. For this reason, complementary and alternative medicine has generated interest as a natural chance linked to disease prevention. Natural antioxidant supplementation has been investigated to support the reduction of bone loss caused by oxidative stress (31).
Green tea, for instance, is well-known for its content in phenolic compounds including (–)-epigallocatechin 3-gallate (EGCG), (–)-epicatechin gallate (ECG), (–)-epicatechin (EC), and (–)-epigallocatechin (Figure 2A). Shen et al. (32, 33) reported that green tea polyphenols inlet reduces degeneration of bone microarchitecture in rats with chronic inflammation by the downregulation of TNF-α modulating cancellous and endocortical bone compartments. Between Green tea active components, epigallocatechin gallate has attracted attention for its potential health benefits and this molecule was largely investigated for its effect on osteoporosis. The bone formation was affected by EGCG through the enhancement of the alkaline phosphatase activity in osteoblastic cells and bone mineralization, related to the suppression of the osteoclast cells differentiation and of the formation of oxidative stress-induced calcium stone formation in rats (34).
Figure 2. (A) Structures of main green tea polyphenols. (B) Quercitrin. (C) Taxifolin.
Vester et al. (35) demonstrated that stimulation of primary human osteoblasts with low doses of green tea extracts during oxidative stress over 21 days improved mineralization and had beneficial effect on extra-cellular matrix production with higher gene expression of osteocalcin and collagen1α1 during osteoblasts differentiation.
Anthocyanins are water-soluble glycosides including a variety of compounds comprising pelargonidin, cyanidin, delphinidin, peonidin, petunidin, malvidin (Figure 3) (36). The health effects of anthocyanins are mainly due to their ability to impair oxidative stress (37). Anthocyanin chalcones and quinoidal bases with a double bond linked to the keto group are antioxidants in scavenging free radicals (38). Therefore, berry food and drinks could diminish the effects of age-related bone loss and decrease the risk of osteoporosis in humans (39).
Figure 3. Structures of main anthocyanins.
In other studies, Devareddy et al. reported that 5% blueberry treatment (w/w) for 100 days inhibited the loss of whole-body bone mineral density due to the ovariectomy in rats, and suppressed femoral mRNA levels of bone turnover biomarkers that were enhanced by estrogen deficiency (40).
Phloridzin, a dihydrochalcone contained in apples, apples juice, and purees, has been demonstrated to contribute to the antioxidant activity (Figure 4A). The activity of phloridzin on glucose uptake and diabetes has been explored and reported in many research works (41). The phlorizdin intake displayed a protection against ovariectomy-induced osteopenia under inflammatory patterns by the downregulation of inflammation markers and bone resorption (42).
Figure 4. Structures of phloridzin (A), oleuropien (B), and resveratrol (C).
In a murine model, Kim et al. found that phloretin (not glucoside form of phloridzin) inhibited receptor activator of NF-κB ligand (RANKL)-induced formation of multinucleated osteoclasts and diminished bone resorption area produced during the osteoclast differentiation process (43).
Oleuropein (Figure 4B), a secoiridoids esterified with hydroxytyrosol found in the olive tree and derivates, is well-known for its pharmacological activities including antioxidant, anti-inflammatory, anti-cancer, antimicrobial, and antiviral, cardioprotective against acute adriamycin cardiotoxicity, anti-ischemic, and hypolipidemic (44, 45). Puel et al. displayed the dose-dependent bone-sparing effect of oleuropein showing a reduction of bone loss and at the same time a downregulation of inflammatory biomarkers in ovariectomized rats (46).
Resveratrol (Figure 4C) is a stilbene phytoalexin found in many plant species and it is crucial polyphenol found in red wine. It has been considered that dietary resveratrol could affect as an antioxidant, promoting nitric oxide production, platelet aggregation and enhancing high-density lipoprotein cholesterol. In addition, resveratrol was shown to be a chemo preventive agent and exhibits anti-inflammatory, neuroprotective, and antiviral properties (28, 47).
The PGF2α-effect on OPG synthesis was suppresses by resveratrol through the inhibition of the MAP kinase pathways in osteoblasts (48).
Also, resveratrol downregulates bone morphogenic protein-4 (BMP-4) and stimulates VEGF synthesis through the inhibition of p70 S6 kinase in osteoblasts (49) via sirtuin-1 (SIRT1) activation (50).
The effect of above described compounds on osteoblast and osteoclast activity, are summarized in Table 1 (16, 19, 20, 26, 29, 35, 37, 39, 43–45, 50–52).
Table 1. Effect of different polyphenols on osteoclasts and osteoblasts activity in vitro.
Periodontal Disease
Periodontitis is a devastating inflammatory disease of tooth-supporting tissues, which are composed by cementum, periodontal ligament, and alveolar bone, due to imbalance between oxidative stress and antioxidant activity.
Of note, inflammatory stimulation by periodontal bacteria increases the production of crevicular fluid and modulate the production of leukocytes, which, in order to deactivate periodontal pathogens, liberate single oxygen, and hypochlorous acid into the crevicular fluid (53).
The subsequent oxidative stress is counteracted by the antioxidant activity of ascorbate, albumin, and urate characteristic of the crevicular fluid and derived from plasma. When there is instability between oxidative stress and antioxidant activity, periodontal tissue demolition may appear. These remarks suggest that antioxidant rich diets might protect periodontal tissue from development and progression of pathologies, particularly in subjects exposed to environmental and dietary sources of oxidative stress (54, 55).
Based on clinical studies about the biochemical properties delivery of polyphenols formulations there is emerging line of natural therapies for periodontitis that may maximize and improved oral health among more populations. Actually, administration of tea polyphenols, by holding green or black tea, in the mouth for 2–5 min enhance the antioxidant capacity of saliva, and daily use of two fresh grapefruits for 2 weeks increases the phagocytic capability of the polymorphonuclear leucocytes inside the gingival crevicular fluid (56).
Following these suggestions polyphenoids may be employed in dentistry as a prophylaxis against bacterial infection and plaque formation, and as adjuvant therapies to aid post-operative healing of dental sockets and other traumatized tissues. Remarkable, in a recent study researchers find out that quercitrin, a glicoside of quercetin, and ramnose (Figure 2B) present in tartary buckwheat and in the bark of several oak, was found bioactive in vitro on human gingival fibroblasts, downregulating the gene expression of markers linked to inflammation and overexpressing genes that modulate different categories of collagen (57). Matsumoto et al. have reported that a citrus flavonoid 3,5,6,7,8,3′,4′-Heptamethoxyflavone (HMF) (Figure 5) found in Valencia oranges clearly suppressed the osteoclast formation and PGE2 production induced by IL-1. In mouse calvarial organ cultures, HMF attenuated the bone resorption elicited by LPS. HMF inhibits bone resorption induced by inflammation preserving bone mass and contributing to keep away from tooth loss (58).
Figure 5. Structure of 3,5,6,7,8,3,4-Heptamethoxyflavone.
Potential Applications in Oral Medical Devices
Due to recent progression in molecular biology and in the bone remodeling pathways many polyphenols are believed promising molecules able to act on osteoblast differentiation and on mineralization without the high financial impact of other osteoinductive factors.
These results are correlated with an exciting application of flavonoids like bioactive surfaces that could be an option to the use of growth factors i.e., in oral medical devices (59). Noteworthy, the use of growth factors, such as BMPs, in biomedical devices has lately gained several negative points regarding its stability, administration, bioactivity, and bioavailability. They are frequently very expensive and very limited in respect on the regulatory approval (60). By another side, flavonoid compounds are cheap, bioavailable, easy to find in daily food and, for this reason, probably easily be translated into clinical applications. For this rationale plant-derived products represent an innovative and interesting candidates for biomaterial applications, including dental research fields. Biomolecules can be believed as promising field relating to the improving of the bioactivity of biomaterial, and a safe substitute to pharmaceuticals, animal-derived compounds or growth factors. With the aim to attempt to obtain a faster osteointegration to speed up the overall treatment process, the use of biomimetic agents represents an interesting research area related with implant dentistry. For example, the functionalization with flavonoids conferred an osteopromotive characteristic to the Titanium surface as discussed by Cordoba et al. (61). In their study, researchers created a bioactive interface based on the covalent immobilization of flavonoids taxifolin (Figure 2C) and quercitrin on titanium surfaces.
Polyphenols Safety and Toxicity
The consumption of food polyphenols such as flavonoids has been associated with a wide range of health benefits both disease preventive and therapeutic agents, including optimizing cardiometabolic health, cancer prevention, and to a lesser extent positively impacting brain functioning in humans.
Diet-derived polyphenols are considered safe based on their long history of use as food or as traditional medicines, recently it is becoming the idea that these specialized metabolites could have toxic effects at pharmacological concentrations, and in several diseases or polypharmaceutical contexts (62).
The risk of toxic effects is increased using pharmacological doses in prevention/treatment and supplement situations and genetic polymorphisms or molecule–drug interactions that decrease/increase the bioavailability. Few reports on toxicity of these compounds are reported, therefore investigations of the side effects of polyphenols is necessary.
Conclusions
Bone pathologies majorly including osteoporosis osteoarthritis and oral diseases are becoming frequent with the growth in the aging population, a fact which is frightening if we consider the estimations that by 2030 20% of Europeans and 30% of the US population will be over the age of 65. There are only few standard therapies available for the treatment and prevention of these pathologies so a possible protective effect by natural molecules in multifactorial dysmetabolic disease could be a substitute to rise above side effects of conventional therapies.
Majority of the clinical researches underlined in this review, would attempt to demonstrate the relationship between polyphenols intake and bone turnover regulation. However, in spite of abundant in vitro and in vivo animal models, up to the present time, there is an absence of consistent human studies relating with polyphenol consumption. Although it was largely described the main role of antioxidative mechanism of polyphenols in prevention and treatment of bone remodeling diseases, it would be required more studies focused on the application of these compounds as therapeutic alternative in bone resorption diseases.
Author Contributions
VN selected studies and wrote the manuscript and takes responsibility for the manuscript. ND, SN, FC, FB, and RD analyzed and compared literature data, and edited the manuscript. All authors approved the manuscript.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1. Raggatt LJ, Partridge NC. Cellular and molecular mechanisms of bone modeling. J Biol Chem. (2010) 285:25103–8. doi: 10.1074/jbc.R109.041087
2. Chambers TJ, Fuller K. How are osteoclasts induced to resorb bone? Ann NY Acad Sci USA. (2011) 1240:1–6. doi: 10.1111/j.1749-6632.2011.06249.x
3. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. (2003) 423:337–42. doi: 10.1038/nature01658
4. Husheem M, Nyman JK, Vaaraniemi J, Vaananen HK, Hentunen TA. Characterization of circulating human osteoclast progenitors: development of in vitro resorption assay. Calcif Tissue Int. (2005) 76:222–30. doi: 10.1007/s00223-004-0123-z
5. Teitelbaum SL. Osteoclasts: what do they do and how do they do it? Am J Pathol. (2007) 170:427–35. doi: 10.2353/ajpath.2007.060834
6. Bonewald LF, Johnson ML. Osteocytes, mechanosensing and Wnt signaling. Bone. (2008) 42:606–15. doi: 10.1016/j.bone.2007.12.224
7. Everts V, Delaissé JM, Korper W, Jansen DC, Tigchelaar-Gutter W, Saftig P, et al. The bone lining cell: its role in cleaning Howship's lacunae and initiating bone formation. J Bone Miner Res. (2002) 17:77–90. doi: 10.1359/jbmr.2002.17.1.77
8. Nishimura R, Hata K, Matsubara T, Wakabayashi M, Yoneda T. Regulation of bone and cartilage development by network between BMP signalling and transcription factors. J Biochem. (2012) 151:247–54. doi: 10.1093/jb/mvs004
9. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys. (2008) 473:139–46. doi: 10.1016/j.abb.2008.03.018
10. Weitzmann MN, Pacifici R. Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest. (2006) 116:1186–94. doi: 10.1172/JCI28550
11. Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. (2016) 31:16–35. doi: 10.1002/jbmr.2708
12. Faienza MF, Chiarito M, D'Amato G, Colaianni G, Colucci S, Grano M, et al. Monoclonal antibodies for treating osteoporosis. Opin Biol Ther. (2018) 18:149–57. doi: 10.1080/14712598.2018.1401607
13. Sims NA, Ng KW. Implications of osteoblast-osteoclast interactions in the management of osteoporosis by antiresorptive agents denosumab and odanacatib. Curr Osteoporos Rep. (2014) 12:98–106. doi: 10.1007/s11914-014-0196-1
14. Scalbert A, Manach C, Morand C, Rémésy C, Jiménez L. Dietary polyphenols and the prevention of diseases. Crit Rev Food Sci Nutr. (2005) 45:287–306. doi: 10.1080/1040869059096
15. Weaver CM, Alekel DL, Ward WE, Ronis MJ. Flavonoid intake and bone health. J Nutr Gerontol Geriatr. (2012) 31:239–53. doi: 10.1080/21551197.2012.698220
16. Austermann K, Baecker N, Stehle P, Heer M. Putative effects of nutritive polyphenols on bone metabolism in vivo-evidence from human studies. Nutrients. (2019) 11:871. doi: 10.3390/nu11040871
17. Messina M. A brief historical overview of the past two decades of soy and isoflavone research. J Nutr. (2010) 140:1350S−4S. doi: 10.3945/jn.109.118315
18. Zhang G, Qin L, Shi Y. Epimedium-derived phytoestrogen flavonoids exert beneficial effect on preventing bone loss in late postmenopausal women: a 24-month randomized, double-blind and placebo-controlled trial. J Bone Miner Res. (2007) 22:1072–9. doi: 10.1359/jbmr.070405
19. Huang Z, Cheng C, Wang J, Liu X, Wei H, Han Y, et al. Icariin regulates the osteoblast differentiation and cell proliferation of MC3T3-E1 cells through microRNA-153 by targeting Runt-related transcription factor 2. Exp Ther Med. (2018) 15:5159–66. doi: 10.3892/etm.2018.6127
20. Kim B, Lee KY, Park B. Icariin abrogates osteoclast formation through the regulation of the RANKL-mediated TRAF6/NF-κB/ERK signaling pathway in Raw264.7 cells. Phytomedicine. (2018) 51:181–90. doi: 10.1016/j.phymed.2018.06.020
21. Huang J, Yuan L, Wang X, Zhang TL, Wang K. Icaritin and its glycosides enhance osteoblastic, but suppress osteoclastic, differentiation and activity in vitro. Life Sci. (2007) 81:832–40. doi: 10.1016/j.lfs.2007.07.015
22. Bodet C, Chandad F, Grenier D. Cranberry components inhibit interleukin-6, interleukin-8, and prostaglandin E production by lipopolysaccharide-activated gingival fibroblasts. Eur J Oral Sci. (2007) 115:64–70. doi: 10.1111/j.1600-0722.2007.00415.x
23. Yao Z, Xing L, Qin C. Osteoclast precursor interaction with bone matrix induces osteoclast formation directly by an interleukin-1-mediated autocrine mechanism. J Biol Chem. (2008) 283:9917–24. doi: 10.1074/jbc.M706415200
24. Ozaki K, Kawata Y, Amano S, Hanazawa S. Stimulatory effect of curcumin on osteoclast apoptosis. Biochem Pharmacol. (2000) 59:1577–81. doi: 10.1016/S0006-2952(00)00277-X
25. Bharti AC, Takada Y, Aggarwal BB. Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis. J Immunol. (2004) 172:5940–47. doi: 10.4049/jimmunol.172.10.5940
26. Graef JL, Rendina-Ruedy E, Crockett EK, Ouyang P, Wu L, King JB, et al. Osteoclast differentiation is downregulated by select polyphenolic fractions from dried plum via suppression of MAPKs and Nfatc1 in mouse C57BL/6 primary bone marrow cells. Curr Dev Nutr. (2017) 1:e000406. doi: 10.3945/cdn.117.000406
27. Smith BJ, Bu SY, Wang Y, Rendina E, Lim YF, Marlow D, et al. A comparative study of the bone metabolic response to dried plum supplementation and PTH treatment in adult, osteopenic ovariectomized rat. Bone. (2014) 58:151–9. doi: 10.1016/j.bone.2013.10.005
28. de Vries TJ, El Bakkali I, Kamradt T, Schett G, Jansen IDC, D'Amelio P. What are the peripheral blood determinants for increased osteoclast formation in the various inflammatory diseases associated with bone loss? Front Immunol. (2019) 19:505. doi: 10.3389/fimmu.2019.00505
29. Domazetovic V, Marcucci G, Iantomasi T, Brandi ML, Vincenzini MT. Oxidative stress in bone remodeling: role of antioxidants. Clin Cases Miner Bone Metab. (2017) 14:209–16. doi: 10.11138/ccmbm/2017.14.1.209
30. Léotoing L, Wauquier F, Guicheux J, Miot-Noirault E, Wittrant Y, Coxam V. The polyphenol fisetin protects bone by repressing NF-κB and MKP-1-dependent signaling pathways in osteoclasts. PLoS ONE. (2013) 8:e68388. doi: 10.1371/journal.pone.0068388
31. Horcajada MN, Offord E. Naturally plant-derived compounds: role in bone anabolism. Curr Mol Pharmacol. (2012) 5:205–18. doi: 10.2174/1874467211205020205
32. Shen CL, Yeh JK, Stoecker BJ, Chyu MC, Wang JS. Green tea polyphenols mitigate deterioration of bone microarchitecture in middle-aged female rats. Bone. (2009) 44:684–90. doi: 10.1016/j.bone.2008.11.018
33. Shen CL, Yeh JK, Cao JJ, Wang JS. Green tea and bone metabolism. Nutr Res. (2009) 29:437–56. doi: 10.1016/j.nutres.2009.06.008
34. Oka Y, Iwai S, Amano H, Irie Y, Yatomi K, Ryu K, et al. Tea polyphenols inhibit rat osteoclast formation and differentiation. J Pharmacol Sci. (2012) 118:55–64. doi: 10.1254/jphs.11082FP
35. Vester H, Holzer N, Neumaier M, Lilianna S, Nüssler AK, Seeliger C. Green Tea Extract (GTE) improves differentiation in human osteoblasts during oxidative stress. J Inflamm. (2014) 11:15. doi: 10.1186/1476-9255-11-15
36. Slatnar A, Jakopic J, Stampar F, Veberic R, Jamnik P. The effect of bioactive compounds on in vitro and in vivo antioxidant activity of different berry juices. PLoS ONE. (2012) 7:e47880. doi: 10.1371/journal.pone.0047880
37. Aqil F, Gupta A, Munagala R, Jeyabalan J, Kausar H, Sharma RJ, et al. Antioxidant and antiproliferative activities of anthocyanin/ellagitannin-enriched extracts from Syzygium cumini L. (Jamun, the Indian Blackberry). Nutr Cancer. (2012) 64:428–38. doi: 10.1080/01635581.2012.657766
38. Wang H, Cao G, Prior RL. Oxygen radical absorbing capacity of anthocyanins. J Agric Food Chem. (1997) 45:304–9. doi: 10.1021/jf960421t
39. Hubert PA, Lee SG, Lee SK, Chun OK. Dietary polyphenols, berries, and age-related bone loss: a review based on human, animal, and cell studies. Antioxidants. (2014) 3:144–58. doi: 10.3390/antiox3010144
40. Devareddy L, Hooshmand S, Collins JK, Lucas EA, Chai SC, Arjmandi BH. Blueberry prevents bone loss in ovariectomized rat model of postmenopausal osteoporosis. J Nutr Biochem. (2008) 19:694–9. doi: 10.1016/j.jnutbio.2007.09.004
41. Ehrenkranz JRL, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev. (2005) 21:31–8. doi: 10.1002/dmrr.532
42. Puel C, Quintin A, Mathey J, Obled C, Davicco M, Lebecque P, et al. Prevention of bone loss by phloridzin, an apple polyphenol, in ovariectomized ratsunder inflammation conditions. Calcif Tissue Int. (2005) 77:311–8. doi: 10.1007/s00223-005-0060-5
43. Kim JL, Kang MK, Gong JH, Park SH, Han SY, Kang YH. Novel antiosteoclastogenic activity of phloretin antagonizing RANKL-induced osteoclast differentiation of murine macrophages. Mol Nutr Food Res. (2012) 56:1223–33. doi: 10.1002/mnfr.201100831
44. Santiago-Mora R, Casado-Díaz A, De Castro MD, Quesada-Gómez JM. Oleuropein enhances osteoblastogenesis and inhibits adipogenesis: the effect on differentiation in stem cells derived from bone marrow. Osteoporos Int. (2011) 22:675–84. doi: 10.1007/s00198-010-1270-x
45. Chin KY, Ima-Nirwana S. Olives and bone: a green osteoporosis prevention option. Int J Environ Res Public Health. (2016) 13:E755. doi: 10.3390/ijerph13080755
46. Puel C, Mathey J, Agalias A, Kati-Coulibaly S, Mardon J, Obled C, et al. Dose-response study of effect of oleuropein, an olive oil polyphenol, in an ovariectomy/inflammation experimental model of bone loss in the rat. Clin Nutr. (2006) 25:859–68. doi: 10.1016/j.clnu.2006.03.009
47. Sharma S, Anjaneyulu M, Kulkarni SK, Chopra K. Resveratrol, a polyphenolic phytoalexin, attenuates diabetic nephropathy in rats. Pharmacology. (2006) 76:69–75. doi: 10.1159/000089720
48. Kuroyanagi G, Otsuka T, Yamamoto N, Matsushima-Nishiwaki R, Nakakami A, Mizutani J, et al. Down-regulation by resveratrol of basic fibroblast growth factor-stimulated osteoprotegerin synthesis through suppression of Akt in osteoblasts. Int J Mol Sci. (2014) 15:17886–900. doi: 10.3390/ijms151017886
49. Kondo A, Otsuka T, Kuroyanagi G, Yamamoto N, Matsushima-Nishiwaki R, Mizutani J, et al. Resveratrol inhibits BMP-4-stimulated VEGF synthesis in osteoblasts: suppression of S6 kinase. Int J Mol Med. (2014) 33:1013–18. doi: 10.3892/ijmm.2014.1626
50. Zhao M, Ko SY, Garrett IR, Mundy GR, Gutierrez GE, Edwards JR. The polyphenol resveratrol promotes skeletal growth in mice through a sirtuin 1-bone morphogenic protein 2 longevity axis. Br J Pharmacol. (2018) 175:4183–92. doi: 10.1111/bph.14477
51. Murgia D, Mauceri R, Campisi G, De Caro V. Advance on resveratrol application in bone regeneration: progress and perspectives for use in oral and maxillofacial surgery. Biomolecules. (2019) 9:E94. doi: 10.3390/biom9030094
52. Graef JL, Rendina-Ruedy E, Crockett EK, Ouyang P, King JB, Cichewicz RH, et al. Select polyphenolic fractions from dried plum enhance osteoblast activity through BMP-2 signaling. J Nutr Biochem. (2018) 55:59–67. doi: 10.1016/j.jnutbio.2017.09.014
53. Battino M, Bullon P, Wilson M, Newman H. Oxidative injury and inflammatory periodontal diseases: the challenge of anti-oxidants to free radicals and reactive oxygen species. Crit Rev Oral Biol Med. (1999) 10:458–76. doi: 10.1177/10454411990100040301
54. Brunetti G, Colucci S, Pignataro P, Coricciati M, Mori G, Cirulli N, et al. T cells support osteoclastogenesis in an in vitro model derived from human periodontitis patients. J Periodontol. (2005) 76:1675–80. doi: 10.1902/jop.2005.76.10.1675
55. Ritchie CS, Kinane DF. Nutrition, inflammation, and periodontal disease. Nutrition. (2003) 19:475–6. doi: 10.1016/S0899-9007(02)01043-2
56. Staudte H, Sigusch BW, Glockmann E. Grapefruit consumption improves vitamin C status in periodontitis patients. Br Dent J. (2005) 4:213–7. doi: 10.1038/sj.bdj.4812613
57. Gomez-Florit M, Monjo M, Ramis JM. Identification of quercitrin as potential therapeutic agent for periodontal applications. J Periodontol. (2014) 85:966–74. doi: 10.1902/jop.2014.130438
58. Matsumoto C, Inoue H, Tominari T, Watanabe K, Hirata M, Miyaura C, et al. Heptamethoxyflavone, a citrus flavonoid, suppresses inflammatory osteoclastogenesis and alveolar bone resorption. Biosci Biotechnol Biochem. (2015) 79:155–8. doi: 10.1080/09168451.2014.952616
59. Wang Z, Wang D, Yang D, Zhen W, Zhang J, Peng S. The effect of icariin on bone metabolism and its potential clinical application. Osteoporos Int. (2018) 29:535–44. doi: 10.1007/s00198-017-4255-1
60. Junker R, Dimakis A, Thoneick M, Jansen JA. Effects of implant surface coatings and composition on bone integration: a systematic review. Clin Oral Impl Res. (2009) 4:185–206. doi: 10.1111/j.1600-0501.2009.01777.x
61. Cordoba A, Satue M, Gomez-Florit M, Hierro-Oliva M, Petzold C; Lyngstadaas SP, et al. Flavonoid-modified surfaces: multifunctional bioactive biomaterials with osteopromotive, anti-inflammatory, and anti-fibrotic potential. Adv Health Mater. (2014) 4:540–9. doi: 10.1002/adhm.201400587
Keywords: biomolecules, polyflavonoids, bone remodeling, titanium implant, coating surfaces
Citation: Nicolin V, De Tommasi N, Nori SL, Costantinides F, Berton F and Di Lenarda R (2019) Modulatory Effects of Plant Polyphenols on Bone Remodeling: A Prospective View From the Bench to Bedside. Front. Endocrinol. 10:494. doi: 10.3389/fendo.2019.00494
Received: 05 March 2019; Accepted: 08 July 2019;
Published: 23 July 2019.
Edited by:
Giacomina Brunetti, University of Bari Aldo Moro, ItalyReviewed by:
Gabriele D'Amato, U.O.C di Terapia Intensiva Neonatale, Ospedale Di Venere, ItalyMario Rende, University of Perugia, Italy
Copyright © 2019 Nicolin, De Tommasi, Nori, Costantinides, Berton and Di Lenarda. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Vanessa Nicolin, nicolin@units.it